CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Pappas Capital targets $200M at next generation of Asian innovation
News | 09. 24. 2021
Pappas Capital's Asia Innovation Ventures is a $200M fund targeting next generation technologies in Asia. The fund was more than two years in the making and is a way to tap into innovation in China, Hong Kong and Singapore.
